Consumers and their doctors all know about LDL and the need to lower the so-called bad cholesterol. But what about the treatments beyond those that lower LDL? James Stolzenbach, who oversees clinical research in the area of dyslipidemia and renal drug development at Abbott Laboratories, tells host Bruce Japsen about new developments in treating and managing cholesterol beyond lowering LDL.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Beyond LDL: New Treatment Options to Manage Lipids
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
Consumers and their doctors all know about LDL and the need to lower the so-called bad cholesterol. But what about the treatments beyond those that lower LDL? James Stolzenbach, who oversees clinical research in the area of dyslipidemia and renal drug development at Abbott Laboratories, tells host Bruce Japsen about new developments in treating and managing cholesterol beyond lowering LDL.
Presenters
Facebook Comments